How India Exports Salicylic to the World

In the United States, salicylic acid is recognized by the Food and Drug Administration (FDA) as an active ingredient in over-the-counter (OTC) topical acne drug products. According to the FDA's Final Administrative Order OTC000013, issued in December 2025, salicylic acid concentrations ranging from 0.5% to 2% are considered safe and effective for treating acne when formulated appropriately.

The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for salicylic acid formulations, indicating a well-established generic market. However, specific recent approvals and import alerts should be verified through the FDA's official database to ensure compliance with current regulatory standards. Given the presence of 276 active Indian exporters, it is imperative for each to adhere strictly to FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), salicylic acid is subject to stringent regulatory oversight. The European Medicines Agency (EMA) has established guidelines for the approval of low-dose modified-release acetylsalicylic acid formulations, particularly for the secondary prevention of cardiovascular events. These guidelines, adopted in July 2002, outline the necessary requirements for marketing authorization. (ema.europa.eu)

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) mandates that all medicinal products, including those containing salicylic acid, obtain marketing authorization before distribution. Compliance with Good Manufacturing Practice (GMP) standards is essential, ensuring product quality and safety.

Salicylic acid is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in basic healthcare systems. The WHO's inclusion of salicylic acid highlights its critical role in treating various dermatological conditions. Additionally, salicylic acid formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, salicylic acid is regulated by the Central Drugs Standard Control Organization (CDSCO). It is classified under Schedule H, indicating that it is a prescription drug requiring a doctor's prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) monitors the pricing of essential medicines, including those containing salicylic acid, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Salicylic acid, being a well-established compound, is not subject to active patents, allowing for extensive generic competition. This lack of patent protection facilitates the widespread production and export of salicylic acid formulations by multiple manufacturers, contributing to the competitive pricing observed in the market.

In December 2025, the FDA issued the Final Administrative Order OTC000013, which updated the monograph for OTC topical acne drug products, including salicylic acid. This order reaffirmed the safety and efficacy of salicylic acid concentrations between 0.5% and 2% for acne treatment.

In July 2025, the UK's Food Standards Agency (FSA) updated its list of approved additives and E numbers, which includes salicylic acid. This update provides clarity on the permissible use of salicylic acid in various food products, ensuring consumer safety. (food.gov.uk)

In March 2024, the FSA published a safety assessment for guanidinoacetic acid (Creamino®), a feed additive for all animal species. While not directly related to salicylic acid, this assessment reflects the agency's ongoing efforts to evaluate and regulate various acids used in food and feed products. (food.gov.uk)

In January 2024, the FSA provided guidance on plant toxins, including information on naturally occurring acids in food crops. This guidance aims to ensure food safety by addressing potential risks associated with plant-derived compounds. (food.gov.uk)

In October 2025, the FSA announced the mandatory fortification of non-wholemeal wheat flour with folic acid, effective from December 2026. This policy change aims to reduce neural tube defects in newborns and reflects the agency's commitment to public health through nutritional interventions. (food.gov.uk)

These developments underscore the dynamic regulatory environment surrounding acids and their derivatives, highlighting the importance of continuous monitoring and compliance for exporters.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian API manufacturing are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as disruptions in Chinese production or exports can directly impact India's ability to produce APIs, including those for salicylic acid.

Recent geopolitical tensions have exacerbated these risks. In February 2026, the closure of the Strait of Hormuz following military conflicts led to significant disruptions in the supply of raw materials to Asia's petrochemical industry, affecting the availability of essential chemicals for API production. Such events underscore the fragility of the supply chain and the potential for cascading effects on pharmaceutical manufacturing.

Our proprietary trade data indicates that the top five exporters of salicylic acid from India account for 59.0% of total exports, with RECKITT BENCKISER (INDIA) PRIVATE LIMITED alone contributing 21.5%. This high supplier concentration poses a single-source risk; any operational or logistical issues faced by these key exporters could significantly disrupt the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic manufacturing of critical APIs and reduce import dependence. In October 2024, two new plants were inaugurated under this scheme to produce essential molecules for antibiotics, marking a step towards self-reliance. However, the effectiveness of these initiatives in diversifying the supplier base for salicylic acid remains to be fully realized.

The closure of the Strait of Hormuz in February 2026, due to escalating conflicts, has had profound implications for global supply chains. Approximately 20% of the world's oil passes through this chokepoint, and its disruption has led to increased energy costs and logistical challenges. These factors have directly impacted the pharmaceutical industry, causing delays and increased costs in the transportation of APIs and finished products.

Additionally, tensions in the Red Sea and the Strait of Hormuz have forced shipping companies to reroute vessels around the Cape of Good Hope, adding 10 to 14 days to transit times. Such delays can disrupt the timely delivery of pharmaceutical products, including salicylic acid, to global markets.

• Diversify Supplier Base: Encourage the development of alternative suppliers for salicylic acid, both domestically and internationally, to reduce reliance on a concentrated group of exporters.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for APIs and KSMs to decrease dependency on imports, particularly from China.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic reserves of critical raw materials to buffer against geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the pharmaceutical supply chain.

• Collaborate with Regulatory Bodies: Engage with international regulatory agencies to stay informed about potential shortages and coordinate responses to supply chain disruptions.

RISK_LEVEL: HIGH